Physician profile

Joseph Pierre

Family Medicine · Saint Albans, NY

NPI 1659408383

$758.03

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$144.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $262.47 2019-2020
Abbvie INC. $137.18 2021-2024
Sanofi-Aventis U.S. LLC $131.42 2019
Global Blood Therapeutics, INC. $59.27 2020
Lilly USA, LLC $56.60 2020
Allergan, INC. $43.18 2020
Gilead Sciences, INC. $25.83 2023
Astrazeneca Pharmaceuticals LP $22.02 2019
Janssen Pharmaceuticals, INC $20.06 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joseph Pierre

$758.03

in general payments reported 2019-2025

Years
2019-2024
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/638040/joseph-pierre

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.